[Initial clinical experience of proton therapy at Shizuoka Cancer Center].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica Pub Date : 2005-10-01

Shigeyuki Murayama, Hiroshi Fuji, Haruo Yamashita, Yasuyuki Futami, Masumi Numano, Hideyuki Harada, Minoru Kamata, Tetsuo Nishimura

{"title":"[Initial clinical experience of proton therapy at Shizuoka Cancer Center].","authors":"Shigeyuki Murayama, Hiroshi Fuji, Haruo Yamashita, Yasuyuki Futami, Masumi Numano, Hideyuki Harada, Minoru Kamata, Tetsuo Nishimura","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To present the initial experience and preliminary clinical results of patients treated mainly with proton irradiation at the newly developed proton therapy facility at Shizuoka Cancer Center.Materials and methods: We reviewed 125 patients who underwent proton therapy between July 2003 and December 2004. Of these 125 patients, 11 had head and neck malignancies, 15 non-small cell lung cancers, 22 hepatocellular carcinomas, 62 prostate cancers, and 15 other malignant tumors.Results: Most patients experienced Grade 0-1 acute morbidities (NCI-CTC) in skin or mucosa, while a temporary Grade 2-3 reaction was observed in a high dose area. Response rates were 73% for H & N malignancies, 100% for NSCLC, and 77% for HCC. PSA evaluation for patients with prostate cancer revealed a high rate of complete response.Conclusion: The efficacy and safety of proton therapy at Shizuoka Cancer Center was demonstrated for patients with early-stage cancer or locally advanced disease.","PeriodicalId":19251,"journal":{"name":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica","volume":"65 4","pages":"424-31"},"PeriodicalIF":0.0000,"publicationDate":"2005-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To present the initial experience and preliminary clinical results of patients treated mainly with proton irradiation at the newly developed proton therapy facility at Shizuoka Cancer Center.

Materials and methods: We reviewed 125 patients who underwent proton therapy between July 2003 and December 2004. Of these 125 patients, 11 had head and neck malignancies, 15 non-small cell lung cancers, 22 hepatocellular carcinomas, 62 prostate cancers, and 15 other malignant tumors.

Results: Most patients experienced Grade 0-1 acute morbidities (NCI-CTC) in skin or mucosa, while a temporary Grade 2-3 reaction was observed in a high dose area. Response rates were 73% for H & N malignancies, 100% for NSCLC, and 77% for HCC. PSA evaluation for patients with prostate cancer revealed a high rate of complete response.

Conclusion: The efficacy and safety of proton therapy at Shizuoka Cancer Center was demonstrated for patients with early-stage cancer or locally advanced disease.

本刊更多论文

【静冈癌症中心质子治疗的初步临床经验】。

目的:介绍在静冈癌症中心新开发的质子治疗设备中以质子照射为主的患者的初步经验和初步临床结果。材料和方法:我们回顾了2003年7月至2004年12月间接受质子治疗的125例患者。在125例患者中，11例为头颈部恶性肿瘤，15例为非小细胞肺癌，22例为肝细胞癌，62例为前列腺癌，15例为其他恶性肿瘤。结果:大多数患者在皮肤或粘膜出现0-1级急性病变(NCI-CTC)，而在高剂量区观察到暂时的2-3级反应。h&n恶性肿瘤的缓解率为73%，NSCLC为100%，HCC为77%。前列腺癌患者的PSA评估显示完全缓解率高。结论:静冈癌症中心质子治疗对早期癌症或局部晚期癌症患者的有效性和安全性得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica

自引率

0.00%

发文量